A phase 1 open label study to assess the human mass balance and metabolite profile of 14 C-fosmanogepix, a novel Gwt-1 inhibitor in healthy male participants.
Michael R HodgesEric OplePhilip EvansA J Andre PantophletJessica RichardsonDylan WilliamsSakambari TripathyMargaret TawadrousAbhijeet JakatePublished in: Antimicrobial agents and chemotherapy (2024)
This study is registered with ClinicalTrials.gov as NCT04804059.